Zhitong Finance App News, Zaiding Pharmaceutical (09688.HK) announced today the first data from a global phase 1b clinical study evaluating zocilurtatug pelitecan (zoci, formerly ZL-1310) combined with atilizumab (with or without carboplatin) for first-line treatment of extensive small cell lung cancer (ES-SCLC). The data will be presented at the European Society of Medical Oncology (ESMO) 2026 conference in Madrid, Spain.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.